Cristina Suárez
Impact in
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
- Pulmonary and Respiratory Medicine top 0.5%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
Papers in
-
- Renal cell carcinoma treatment 78
- Prostate Cancer Treatment and Research 18
-
- Cancer Genomics and Diagnostics 18
- Co-authors
- Fé Tubau (12 shared papers)Carmen Peña (9 shared papers)Francesc Gudiol (3 shared papers)Thomas Powles (9 shared papers)Joan Carles (32 shared papers)Robert John Motzer (11 shared papers)Camillo Porta (10 shared papers)Laurence K. Albiges (10 shared papers)
- Journals
- Annals of Oncology (20 papers)Clinical & Translational Oncology (8 papers)European Urology (7 papers)The Journal of Physical Chemistry (7 papers)European Journal of Cancer (6 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Cristina Suárez
167 papers receiving 9.7k citations
Cristina Suárez's Hit Papers
Peers
Comparison fields: 5 of 141
- Molecular Medicine 702
- Pulmonary and Respiratory Medicine 4.1k
- Applied Microbiology and Biotechnology 233
- Oncology 2.8k
- Cancer Research 1.4k
Countries citing papers authored by Cristina Suárez
This map shows the geographic impact of Cristina Suárez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Suárez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Suárez more than expected).
Fields of papers citing papers by Cristina Suárez
This network shows the impact of papers produced by Cristina Suárez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Suárez. The network helps show where Cristina Suárez may publish in the future.
Co-authors
The 25 scholars most cited alongside Cristina Suárez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 182 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 2 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 3 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 4 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 457 |
| 5 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 400 |
| 6 | 2007 | 281 | |
| 7 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 228 |
| 8 | Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Hit paper breakdown → | 2021 | 224 |
| 9 | 2011 | 188 | |
| 10 | Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer Hit paper breakdown → | 2024 | 188 |
| 11 | Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2024 | 181 |
| 12 | Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2022 | 168 |
| 13 | 2017 | 162 | |
| 14 | 2021 | 158 | |
| 15 | Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder Hit paper breakdown → | 2022 | 157 |
| 16 | 2013 | 143 | |
| 17 | Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 143 |
| 18 | 2011 | 134 | |
| 19 | 2021 | 130 | |
| 20 | 2012 | 123 |
About Cristina Suárez
Cristina Suárez is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Surgery and Molecular Biology, having authored 182 papers that have together received 9.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (78 papers), Bladder and Urothelial Cancer Treatments (25 papers), Renal and related cancers (23 papers), Cancer Genomics and Diagnostics (18 papers), Prostate Cancer Treatment and Research (18 papers), Cancer Immunotherapy and Biomarkers (10 papers), Molecular spectroscopy and chirality (9 papers) and Antibiotic Resistance in Bacteria (9 papers). The work is most often cited by research in Molecular Medicine (702 citations), Pulmonary and Respiratory Medicine (4.1k citations), Applied Microbiology and Biotechnology (233 citations), Oncology (2.8k citations) and Cancer Research (1.4k citations). Cristina Suárez has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Fé Tubau, Carmen Peña, Francesc Gudiol, Thomas Powles, Joan Carles, Robert John Motzer, Camillo Porta, Laurence K. Albiges, Luis Martı́nez-Martı́nez and Toni K. Choueiri. Their work appears in journals such as Annals of Oncology, Clinical & Translational Oncology, European Urology, The Journal of Physical Chemistry and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.